Controlled-Release Oral Contraceptive for Missed-Dose Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral contraceptives with low doses of ethynyl estradiol (EE) face issues with increased bleeding and adverse events, leading to non-compliance and reduced contraceptive efficacy, while attempts to replace EE with other estrogens result in unacceptable bleeding patterns.
Innovation Solution
A method using an oral contraceptive composition with 2 mg of dienogest (DNG) and 0.02 mg of ethynyl estradiol (EE) in an extended-release matrix, providing controlled release to reduce peak exposure and fluctuations, allowing for missed or delayed administration up to 24 hours without reducing contraceptive efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the dose of ethynyl estradiol (EE) is reduced to ≤35 mcg to decrease incidence of VTEs and adverse events, then safety and tolerability are improved, but bleeding patterns become irregular and contraceptive efficacy decreases
Solution Approach 1:
The patent divides the release of dienogest into two distinct phases: a first phase with rapid release providing initial contraceptive protection, and a second phase with delayed slow release maintaining stable hormone levels. This segmentation allows the use of lower EE doses while maintaining reliability through optimized progestogen release patterns.
Solution Approach 2:
The patent implements periodic dosing with 21 days of active pill intake followed by 7 tablet-free days, creating a regulated cycle that maintains contraceptive efficacy while managing bleeding patterns. This periodic action allows the lower EE dose to be effective when combined with the phased dienogest release.
2Object-affected harmful factors
If the dose of ethynyl estradiol (EE) is reduced to 20 mcg or lower to improve safety, then adverse events decrease, but cycle control and bleeding patterns worsen
Solution Approach 1:
The patent changes the release parameters of dienogest from immediate to controlled two-phase release, transforming the pharmacokinetic profile to maintain stable hormone levels throughout the cycle. This parameter change compensates for the reduced EE dose and maintains cycle control with better bleeding patterns.
Solution Approach 2:
The patent introduces dynamic release characteristics with dienogest that adapts to the physiological cycle - rapid initial release followed by delayed slow release. This dynamic approach maintains stability in cycle control and bleeding patterns despite the lower static EE dose.
3Stability of the object's composition
If dienogest is released in two phases with delayed slow release to maintain stable levels, then cycle control improves, but device complexity increases
Solution Approach 1:
The patent uses composite tablet formulations containing dienogest and ethynyl estradiol with specific excipients that enable the two-phase release mechanism. The composite nature of the formulation achieves complex release patterns through material science rather than mechanical complexity.
Data Source
AI summary
Methods for oral contraception comprising administering an oral contraceptive composition comprising 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest, DNG) and 17α-ethinylestradiol (ethynyl estradiol, EE) are provided. Embodiments of the disclosed methods provide effective contraception with a Pearl Index of less than 0.7 when up to one or two daily oral doses are skipped or delayed.